Taiwan Tati Cultural and Educational Foundation

Home

News

Ma’s choice of Chu more popular than that of Wu

Wednesday, 09 September 2009 08:24 Taipei Times

Wu Den-yih’s (吳敦義) appointment as premier was not as popular as that of vice premier-designate Eric Chu (朱立倫), polls showed yesterday.

A survey conducted by the TVBS Poll Center on Monday night found that 61 percent of respondents said Chu, Taoyuan County commissioner and Chinese Nationalist Party (KMT) vice chairman, was suitable for his new job, while 12 percent said he was unsuitable and 27 percent did not give an opinion.

Magazine lists Ma as one of world’s ‘gutsiest’ leaders

Monday, 07 September 2009 09:12 Taipei Times

President Ma Ying-jeou (馬英九) has been selected as one of the world’s “gutsiest” leaders in the September-October issue of the humorous US public affairs magazine mental_floss.

The author of the article, Jennifer Drapkin, said all the people in it have had unbelievable lives.

Main Menu

228 Tâi-uân-sîn

We're 228 Followers

2015-12-26 Taiwanese Shrine Initation & Marytr-Spirit Enshrine Ceremony

2014-02-28 228 Tâi-uân-sîn(Taiwan gods) Thanksgiving Blessing Assembly and Trong R. Chai Tâi-uân-sîn Thanksgiving Praying Ceremony

2013-08-18 Holy Mountain Holiness Birthday and Tâi-uân-sîn Lin Mao-sheng Statue's Placement Ceremony

2013-02-28 228 Tâi-uân-sîn Thanksgiving Prayer Assembly - Realized the Determination of Founding Taiwan State with Democratic Power

228 Memorial and Bian Casters Gathering on Feb. 28th, 2010

Newsflash

Taiwan’s indigenously developed Medigen COVID-19 vaccine is as effective in preventing deaths and serious symptoms as mRNA shots, a study to be published in the US Centers for Disease Control and Prevention’s journal next month showed.

An early release of the study is available on the Web site of the Emerging Infectious Diseases journal.

The study, conducted by the Centers for Disease and Control (CDC), utilized data from Taiwan’s records of inoculations, hospitalizations and deaths since the local outbreak of the Omicron variant of SARS-CoV-2 in 2022.